|
Topotecan (T) and Cisplatin (C) Both Administered as Refracted 5-Day Doses: A Phase I, Dose Finding, Study. |
|
|
Leadership - Personal Genome Diagnostics |
Stock and Other Ownership Interests - PapGene, Inc.; Personal Genome Diagnostics |
Consulting or Advisory Role - Genentech; Merck; Personal Genome Diagnostics |
Speakers' Bureau - Cell Design Labs |
Research Funding - Merck (Inst) |
Patents, Royalties, Other Intellectual Property - PapGene, PGDx and other entities have licensed several patent applications from Johns Hopkins, where Dr. Diaz is an inventor. These relationships are subject to certain restrictions under Johns Hopkins University policy, and the terms of these arrangement |
Travel, Accommodations, Expenses - Merck |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck |
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck |
|
|
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst) |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche |